Table 5.
Therapeutic strategies for COVID-19 and outcomes
| Study population | Results |
| Patients, n | 57 |
| Medications, n (%) | |
| Steroids (for COVID-19) | 19 (35) |
| Antibiotics | 35 (63) |
| Azitromycin | 15 (27) |
| >1 antibiotic | 16 (29) |
| Antivirals | 5 (9) |
| Lopinavir/ritonavir | 3 (5) |
| Darunavir/cobicistat | 1 (2) |
| Remdesivir | 1 (2) |
| Immunomodulator | 3 (5) |
| Tocilizumab | 1 (2) |
| Rituximab | 1 (2) |
| Ruxolitinib | 1 (2) |
| Hydroxychloroquine | 24 (44) |
| Oxygen therapy (higher intensity), n (%) | |
| Overall | 30 (54) |
| Nasal cannula | 18 (32) |
| Non-invasive ventilation | 8 (14) |
| Invasive mechanical ventilation | 4 (7) |
| Outcomes, n (%) | |
| Death | 7 (12) |
| ARDS | 11 (19) |
| ICU admission | 4 (7) |
| Hospitalisation (no ICU) | 37 (65) |
| Need for rehabilitation | 7 (17) |
| Duration of hospitalisation, median (IQR) | |
| Hospital stay | 10 (7–22) |
| ICU stay | 16 (10–19) |
| Rehab stay | 14 (11–15) |
ARDS, acute respiratory distress syndrome; ICU, intensive care unit.